BBOX1 and hepatocellular carcinoma: CCK-8 assays showed that overexpression of BBOX1-AS1 remarkably weakened the cytotoxicity of sorafenib in HCC cells, while BBOX1-AS1 silencing enhanced the anticarcinogenic effect of sorafenib (Figure 3B).